NCT01457573View on ClinicalTrials.gov

Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Lower Urinary Tract Symptoms
Interventions
DRUG

Tamsulosin

Alpha blocker used to in the treatment of urinary difficulties related to enlarged prostate or symptomatic benign prostatic hypertrophy. All men will receive Tamsulosin (Flomax®) 0.4 mg, 1 tab, per morning with Solifenacin (Vesicare®).

DRUG

Solifenacin

Antispasmodic/anticholinergic used to treat overactive bladder. All men will receive Solifenacin (Vesicare®) 5 mg, 1 tab, per morning with Tamsulosin.

Trial Locations (1)

77030

The Methodist Hospital System, Houston

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Timothy Boone, MD, PhD

OTHER

NCT01457573 - Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms | Biotech Hunter | Biotech Hunter